Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Lumos Diagnostics Holdings Ltd. has received a second US$5 million payment from Hologic, Inc., totaling US$10 million under an IP agreement for exclusive licensing of Lumos’ technologies in Hologic’s upcoming fetal fibronectin diagnostic product. This marks progress in their multi-phase development agreement aimed at improving women’s health diagnostics. The payment strengthens Lumos’ balance sheet, aiding in its strategic goals.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
